Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07915739
PHASE3

Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer

Sponsor: Mahidol University

View on ClinicalTrials.gov

Summary

This multicenter randomized controlled trial evaluates whether internal mammary node irradiation (IMNI) improves oncologic outcomes in patients with breast cancer who have residual pathologically positive lymph nodes after neoadjuvant systemic therapy. Eligible participants will be randomly assigned in a 1:1 ratio to receive locoregional radiotherapy either with or without irradiation of the internal mammary lymph nodes. The primary outcome is disease-free survival. Secondary outcomes include overall survival, breast cancer mortality, locoregional recurrence-free survival, distant metastasis-free survival, and treatment-related toxicity, particularly cardiac and pulmonary toxicity. A total of 1,760 participants are planned to be enrolled across multiple centers in Thailand.

Official title: Internal Mammary Node Irradiation Versus Omission of Internal Mammary Node Irradiation in Breast Cancer Treated With Neoadjuvant Systemic Therapy: A Phase III Multicenter Randomized Trial

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1760

Start Date

2027-07-01

Completion Date

2036-07-01

Last Updated

2026-11-13

Healthy Volunteers

No

Interventions

RADIATION

Locoregional Radiotherapy With Internal Mammary Node Irradiation

Adjuvant locoregional radiotherapy to the breast or chest wall and regional lymph nodes, including the internal mammary lymph nodes. Allowed dose-fractionation schedules include 50 Gy in 25 fractions, 42.5 Gy in 16 fractions, or 40 Gy in 15 fractions, according to the study protocol.

RADIATION

Locoregional Radiotherapy Without Internal Mammary Node Irradiation

Adjuvant locoregional radiotherapy to the breast or chest wall and regional lymph nodes, with intentional omission of the internal mammary lymph nodes. Allowed dose-fractionation schedules include 50 Gy in 25 fractions, 42.5 Gy in 16 fractions, or 40 Gy in 15 fractions, according to the study protocol.

Locations (9)

Siriraj Hospital

Bangkok, Bangkok Noi, Thailand

Chulabhorn Hospital

Bangkok, Thailand

Chonburi Cancer Hospital

Chon Buri, Thailand

Vibharam Amata Nakorn Cancer Hospital

Chon Buri, Thailand

Lop Buri Cancer Hospital

Lopburi, Thailand

Synphaet Hospital Nakhon Pathom

Nakhon Pathom, Thailand

Maharaj Nakhon Si Thammarat Hospital

Nakhon Si Thammarat, Thailand

Ratchaburi Hospital

Ratchaburi, Thailand

Metropolitan Hospital Tha Chalom, Samut Sakhon Hospital

Samut Sakhon, Thailand